607 results on '"Brouwers, A H"'
Search Results
2. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)
3. How nuclear imaging changed parathyroid surgical strategies through time
4. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism
5. Update on the Role of [18F]FDOPA PET/CT
6. Towards in vivo characterization of thyroid nodules suspicious for malignancy using multispectral optoacoustic tomography
7. 18F-fluorocholine PET/MRI versus ultrasound and sestamibi for the localization of parathyroid adenomas
8. Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations
9. Optimisation of scan duration and image quality in oncological 89Zr immunoPET imaging using the Biograph Vision PET/CT
10. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
11. EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data
12. Patient-derived parathyroid organoids as a tracer and drug-screening application model
13. [18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial
14. Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT.
15. First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner
16. Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
17. Convolutional neural networks for automatic image quality control and EARL compliance of PET images
18. Shortened duration whole body 18F-FDG PET Patlak imaging on the Biograph Vision Quadra PET/CT using a population-averaged input function
19. Extending the clinical capabilities of short- and long-lived positron-emitting radionuclides through high sensitivity PET/CT
20. Imaging Brain Metastases of Neuroendocrine Tumors
21. Targeted optical fluorescence imaging: a meta-narrative review and future perspectives
22. Digital PET systems
23. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma
24. Advances and challenges in immunoPET methodology.
25. Ultrashort Oncologic Whole-Body [18F]FDG Patlak Imaging Using LAFOV PET.
26. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
27. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
28. Use of population input functions for reduced scan duration whole-body Patlak 18F-FDG PET imaging
29. A retrospective analysis of the diagnostic performance of 11C-choline PET/CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant imaging in primary hyperparathyroidism
30. The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors
31. High rate of unexpected lymphatic drainage patterns and a high accuracy of the sentinel lymph node biopsy in oral cancer after previous neck treatment
32. A Novel and Generic Workflow of Indocyanine Green Perfusion Assessment Integrating Standardization and Quantification Toward Clinical Implementation
33. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism
34. Imaging Brain Metastases of Neuroendocrine Tumors
35. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
36. Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis
37. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms
38. Current and Future Use of Long Axial Field-of-View Positron Emission Tomography/Computed Tomography Scanners in Clinical Oncology
39. Patient-Derived Medullary Thyroid Cancer Organoids; a Model for Patient-tailored Drug and PET-Tracer Screening
40. Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for89Zr-Trastuzumab
41. NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk
42. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism.
43. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.
44. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
45. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
46. Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT
47. Optimization of parathyroid 11C-choline PET protocol for localization of parathyroid adenomas in patients with primary hyperparathyroidism
48. [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
49. Ultra‐low dose CT scanning for PET/CT.
50. Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for 89Zr-Trastuzumab.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.